| Property | Value |
|---|
|
?:abstract
|
-
Drug repurposing is a fast way to rapidly discover a drug for clinical use In such circumstances of the spreading of the highly contagious COVID-19, searching for already known drugs is a worldwide demand In this study, many drugs were evaluated by molecular docking Among the test compounds, aliskiren (the best), dipyridamole, mopidamol and rosuvastatin showed higher energies of binding than that of the co-crystallized ligand N3 with COVID-19 main protease M supro /su Rolitetracycline showed the best binding with the catalytic center of the protease enzyme through binding with CYS 145 and HIS 41 Metamizole showed about 86 % of the binding energy of the ligand N3 while the protease inhibitor darunavir showed little bit lower binding energy than N3 These results are promising for using these drugs in the treatment and management of the spreading of COVID-19 virus Also, it could stimulate clinical trials for the use of these drugs by systemic or inhalation route /The results stimulate the evaluation of these drugs as antCOVID-19 especially aliskiren which showed the highest score of binding with the binding site of N3 This will be added to its renin inhibition and advantage of renin inhibition and possibility of the reduced expression of ACE2[12] Dipyridamole and mopidamol showed a potential to be more M supro /suinhibitor than ligand N3 and darunavir Also, dipyridamole has the property of antiviral activity beside its use to decrease the hypercoagulabilty that happens due to COVID infection in addition to the property of promoting type interferon (IFN) responses and protect mice from viral pneumonia [30] Rolitetracycling is an amazing in its binding mode in the active site of the protease pocket it seemed as it is tailored to be buried in that pocket Mopidamol and rosuvastatin are slightly better than the co-crystallized ligand N3 and darunavir in binding mode which nominate the as COVID-19 protease inhibitors Hopefully this study will helin the repurposing a drug for the treatment of COVID-19 /
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}